摘要
在基因组上决定基因差异表达的调控机制被称为表观遗传机制。组蛋白和RNAi的DNA甲基化、乙酰化和磷酸化是典型的例子。这些表观遗传修饰是正常生长和代谢的重要决定因素;同时,异常的组蛋白修饰在病理条件中起着重要作用,在过去几十年里正在成为一个新的研究领域。组蛋白癌修饰是科学界引入的一个术语,用来表示与癌症发展和进展相关的组蛋白翻译后修饰。这些修改很可能在某些条件下作为对环境和社会因素的适应机制。因此,调节DNA甲基化和组蛋白修饰的酶已成为癌症治疗和化学预防的靶点。由于氧化应激已被证明可以调节表观遗传变化,而具有强大抗氧化特性的植物化合物在疾病预防中起着重要作用。如今,“营养表观遗传学”正成为一个新兴的研究表观遗传学影响的领域。本综述旨在讨论有前途的植物化合物的生物学功效,能够抵消有害的表观遗传修饰,特别是组蛋白共生。
关键词: 植物化合物,表观遗传学,组蛋白修饰,DNA甲基化,乙酰化,磷酸化。
图形摘要
Current Drug Targets
Title:Targeting Histone Onco- Modifications Using Plant-Derived Products
Volume: 22 Issue: 11
关键词: 植物化合物,表观遗传学,组蛋白修饰,DNA甲基化,乙酰化,磷酸化。
摘要: The regulatory mechanisms lying over the genome that determines the differential expression of genes are termed epigenetic mechanisms. DNA methylation, acetylation, and phosphorylation of histone proteins and RNAi are typical examples. These epigenetic modifications are important determinants of normal growth and metabolism; at the same time, aberrant histone modifications play a major role in pathological conditions and are emerging as a new area of research for the last decades. Histone onco-modification is a term introduced by the scientific world to denote histone post-translational modifications that are associated with cancer development and progression. These modifications are likely to act in certain conditions as adaptive mechanisms to environmental and social factors. The enzymes that regulate DNA methylation as well as histone modifications are thus become a target for cancer therapy and chemoprevention. Since oxidative stress has been shown to modulate epigenetic changes, and phytocompounds with powerful antioxidant properties have a significant role in disease prevention. Nowadays, “nutri- epigenetics” is becoming an emerging area of research that deals with the influence of dietary compounds in epigenetics. This review aims to discuss the biological efficacy of promising phytocompounds that are able to counteract deleterious epigenetic modifications, especially histone onco- modifications.
Export Options
About this article
Cite this article as:
Targeting Histone Onco- Modifications Using Plant-Derived Products, Current Drug Targets 2021; 22 (11) . https://dx.doi.org/10.2174/1389450122666210118150716
DOI https://dx.doi.org/10.2174/1389450122666210118150716 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Current Pharmaceutical Design LPTS: A Novel Tumor Suppressor Gene and a Promising Drug Target for Cancer Intervention
Recent Patents on Anti-Cancer Drug Discovery The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design The Biphasic Expression Pattern of miR-200a and E-cadherin in Epithelial Ovarian Cancer and its Correlation with Clinicopathological Features
Current Pharmaceutical Design Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry Anticancer Activities of New N-hetaryl-2-cyanoacetamide Derivatives Incorporating 4,5,6,7-Tetrahydrobenzo[b]thiophene Moiety
Anti-Cancer Agents in Medicinal Chemistry Strategies for In Vivo siRNA Delivery in Cancer
Mini-Reviews in Medicinal Chemistry Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Nonviral Approach for Targeted Nucleic Acid Delivery
Current Medicinal Chemistry Applications of Molecular Imaging in Cancer Gene Therapy
Current Gene Therapy Trebananib (AMG 386): A Non-VEGF Antiangiogenesis Option in Women with Ovarian Cancer
Current Angiogenesis (Discontinued) Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers
Current Medicinal Chemistry Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors
Current Diabetes Reviews Molecular Delivery of Plasmids for Genetic Vaccination
Current Pharmaceutical Biotechnology Phosphonomethoxyalkyl Analogs of Nucleotides
Current Pharmaceutical Design What Have We Learned from the Novel Human Cytochromes P450 Hidden in the Databases?
Current Genomics Cellular Senescence as a Target in Cancer Control
Current Cancer Therapy Reviews